| 59.4% |  | United States |
| 8.7% |  | United Kingdom |
| 5% |  | Canada |
| 4% |  | Australia |
| 3.5% |  | Philippines |
| 2.6% |  | Netherlands |
| 2.4% |  | India |
| 1.6% |  | Germany |
| 1% |  | France |
| 0.7% |  | Poland |
| Today: | 207 |
| Yesterday: | 251 |
| This Week: | 207 |
| Last Week: | 2221 |
| This Month: | 4795 |
| Last Month: | 6796 |
| Total: | 129394 |
Contents
Written by EMCDDA | 
| 
| 
| Reports - EMCDDA Report on the risk assessment of GHB |
Drug Abuse
Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs
Use of GHB as a medicinal product (EMEA)
Review of the pharmacotoxicological data on gamma-hydroxybutyric acid (GHB)
Sociological and criminological (Europol) evidence on the risks of GHB
Public health risks of GHB — epidemiological evidence
Participants in the risk-assessment process
| Next > |
|---|